3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Neoplasms
2
Lymphoma, Non-Hodgkin
2
Carcinoma, Renal Cell
2
Zollinger-Ellison Syndrome
1
Uterine Cervical Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Philadelphia Chromosome
1
Melanoma
1
Lymphoproliferative Disorders
1
Lymphomatoid Granulomatosis
1
Lymphoma, Follicular
1
Lymphoma
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Gastrointestinal Cancer Metastatic
1
Epstein-Barr Virus Infections
1
Carcinoma, Hepatocellular
1
Blast Crisis
1
Adenoma, Islet Cell
1
Interventions
Imatinib Mesylate
60
Cyclophosphamide
57
fludarabine phosphate
51
fludarabine
43
Whole-Body Irradiation
41
Mycophenolic Acid
41
Tacrolimus
33
nilotinib
31
Dasatinib
31
Busulfan
29
Peripheral Blood Stem Cell Transplantation
23
Cyclosporine
22
Melphalan
21
Thiotepa
20
Granulocyte Colony-Stimulating Factor
19
Filgrastim
18
thymoglobulin
17
Cytarabine
17
Antilymphocyte Serum
15
Stem Cell Transplantation
14
sargramostim
13
Methotrexate
13
ponatinib
12
asciminib
10
Cyclosporins
10
Cord Blood Stem Cell Transplantation
10
bosutinib
9
Rituximab
9
Interferon-alpha
9
Clofarabine
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
×
Interferons
×
Clear all
NCT00763763
2011-10-05
AFR07
Assistance Publique - Hôpitaux de Paris
Phase 2
Completed
55 enrolled